Stock Analiz

TherapeuticsMD, Inc. TXMD

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.87Market cap $22M
Open the interactive analysis →

TherapeuticsMD, Inc. (TXMD) is a healthcare company listed in the US with a market value of about $22M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of $122000, a net margin of 3.3%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a P/E of 187.0, 5-year revenue growth of -46% a year, a 5-year average ROIC of -22%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.

About TherapeuticsMD

TherapeuticsMD is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $15M in 2014 to $3M in 2025, a decline of about 13.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 24% over three years (dilution for shareholders).

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)187.0
Forward P/E—
P/FCF—
P/S5.8
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−99%

Growth and quality

Revenue growth (1 yr)71.6%
Revenue growth (5 yrs, per year)-45.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1494.6%
ROIC (5-yr avg.)-21.8%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$4M$3M$2M$1M$70M$3M$65M$50M$16M$17M$19M
Net income$122000-$569000-$2M-$10M$112M-$172M-$184M-$176M-$133M-$77M-$90M
Free cash flow—————-$143M-$160M-$168M-$107M-$76M-$70M
EPS (diluted)$0.01$-0.05$-0.19$-0.00$11.96$-21.66$-0.67$-0.72$-0.59$-0.37$-0.46
Net margin3.3%-18.8%-123.8%-789.4%160.1%-6700.9%-282.9%-354.8%-823.7%-458.5%-464.3%
ROIC—-10.5%-17.5%-22.7%2.1%-60.4%-98.6%-55.7%-60.2%-47.2%-55.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is TherapeuticsMD’s P/E ratio?

About 187.0, based on the last twelve months of diluted earnings per share.

Is TherapeuticsMD stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does TherapeuticsMD pay a dividend?

Not currently.

Is TherapeuticsMD a good stock to buy?

We do not give buy or sell advice. TherapeuticsMD scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.